NeuroPace, Inc. (NPCE) - What Are Brokerages Saying About This Stock?

Key Points

• Analysts remain broadly optimistic: NeuroPace has a “Moderate Buy” consensus from 10 analysts, with seven buys and one strong buy. The average 12-month price target is $19.33, above the reported $12.24 share price.
• Institutional ownership is substantial: Hedge funds and other institutional investors own 78.83% of NeuroPace, while First Light Asset Management increased its stake by 16.3% in the second quarter.
• The company remains unprofitable despite beating quarterly estimates: NeuroPace reported an adjusted loss of $0.18 per share versus the expected $0.22 loss, and revenue of $22.83 million exceeded expectations. Analysts forecast a full-year loss of $0.67 per share.

Shares of NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) have received an average recommendation of "Moderate Buy" from the ten research firms that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $19.33.

A number of research analysts recently issued reports on the company. Cantor Fitzgerald restated an "overweight" rating on shares of NeuroPace in a research note on Tuesday, September 15th. HC Wainwright reiterated a "buy" rating and issued a $20.00 price objective on shares of NeuroPace in a research note on Wednesday, July 29th. Raymond James Financial set a $21.00 price objective on NeuroPace in a report on Tuesday, September 15th. Mizuho began coverage on shares of NeuroPace in a research report on Thursday, July 23rd. They set an "outperform" rating and a $22.00 target price on the stock. Finally, Weiss Ratings cut shares of NeuroPace from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday, October 2nd.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. First Light Asset Management LLC increased its stake in NeuroPace by 16.3% in the second quarter. First Light Asset Management LLC now owns 2,861,167 shares of the company's stock valued at $45,464,000 after purchasing an additional 401,201 shares during the period. Bank of America Corp DE purchased a new stake in shares of NeuroPace in the second quarter valued at about $322,000. Man Group plc acquired a new stake in shares of NeuroPace during the second quarter worth about $1,336,000. Hsbc Holdings PLC acquired a new stake in shares of NeuroPace during the second quarter worth about $420,000. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of NeuroPace during the second quarter worth about $351,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

NeuroPace Stock Performance

NASDAQ NPCE opened at $12.24 on Friday. The company has a fifty day moving average of $14.01 and a two-hundred day moving average of $15.17. The company has a market capitalization of $420.08 million, a PE ratio of -21.47 and a beta of 1.86. NeuroPace has a 1 year low of $9.22 and a 1 year high of $19.60. The company has a debt-to-equity ratio of 4.97, a current ratio of 4.94 and a quick ratio of 3.91.

NeuroPace (NASDAQ:NPCE - Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.04. NeuroPace had a negative return on equity of 105.64% and a negative net margin of 19.34%. The business had revenue of $22.83 million for the quarter, compared to analysts' expectations of $22.61 million. As a group, analysts expect that NeuroPace will post -0.67 earnings per share for the current year.

About NeuroPace

NeuroPace, Inc is a medical device company focused on developing and commercializing therapies for people with drug-resistant epilepsy. The company's principal product is the RNS System, an implantable responsive neurostimulation device designed to monitor brain activity, identify abnormal electrical patterns associated with seizures, and deliver targeted stimulation intended to help prevent or reduce seizures.

The RNS System includes an implanted neurostimulator, leads placed in or on the brain, and external tools that support device programming, patient monitoring, and the collection of seizure-related data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.